Univariate analysis evaluating factors predicting positive anti- SARS-CoV-2 serology
| . | Ab expression, n (%) . | . | |||||
|---|---|---|---|---|---|---|---|
| Variables . | Positive . | Negative . | Total . | P . | Odds ratio . | 95% CI . | |
| Analysis of entire cohort (n = 149) | |||||||
| Age at time of vaccination, y | ≤60 | 29 (50.0) | 29 (50.0) | 58 | .844 | 1 | 0.96-1.02 |
| >60 | 47 (51.6) | 44 (48.9) | 91 | — | — | — | |
| Sex | Female | 32 (52.5) | 29 (47.5) | 61 | .481 | 1.26 | 0.66-2.4 |
| Male | 41 (46.6) | 47 (53.4) | 88 | ||||
| Disease type | Indolent lymphoma | 38 (48.1) | 42 (52.5) | 80 | .87 | 1.04 | 0.55-2.00 |
| Aggressive lymphoma | 34 (49.3) | 35 (50.7) | 69 | — | — | — | |
| ALC (111 evaluated patients) | ≤0.9 × 103 /µL | 9 (20.5) | 35(79.5) | 44 | .002 | 3.32 | 1.53-7.21 |
| >0.9 × 103/µL | 42(54.5) | 35(45.5) | 77 | — | — | — | |
| Treatment status (detailed) | Treatment naïve | 25 (89.3) | 3 (10.7) | 28 | <.001 | 1 | |
| Active therapy* | 4(7.3) | 51 (92.7) | 55 | — | 0.039 | 0.01-0.12 | |
| After therapy | 44 (66.7) | 22 (33.3) | 66 | — | 4.17 | 1.13-15.32 | |
| Exposure to any anti-CD20 Abs | No | 25 (89.3) | 3 (10.7) | 28 | <.001 | 0.08 | 0.02-0.27 |
| Yes | 48(39.7) | 73(60.3) | 121 | — | — | — | |
| Analysis of patients treated with anti-CD20 abs (n = 121) | |||||||
| Age in time of vaccination, y | ≤60 | 20 (40.8) | 29 (59.2) | 49 | .832 | 1.08 | 0.52-2.27 |
| >60 | 28 (38.9) | 44 (61.1) | 72 | — | — | — | |
| Sex | Female | 18 (40.0) | 27 (60.0) | 45 | .954 | 0.98 | 0.46-2.08 |
| Male | 30 (39.5) | 46 (60.5) | 76 | — | — | — | |
| Disease type | Indolent lymphoma | 17 (30.9) | 38 (69.1) | 55 | .07 | 1.98 | 0.94-4.2 |
| Aggressive lymphoma | 31 (47.0) | 35 (53.0) | 66 | — | — | — | |
| ALC (107 evaluated patients) | ≤0.9 × 103/µL | 11(22.0) | 39 (78.0) | 50 | .006 | 3.19 | 1.37-7.45 |
| >0.9 × 103/µL | 27 (47.4) | 30(52.6) | 57 | — | — | — | |
| Time since last anti-CD20 abs (mo) | >6 mo | 44(66.7) | 22 (33.3) | 66 | <.001 | 25.5 | 8.16-77.6 |
| ≤6 mo | 4(7.3) | 51(92.7) | 55 | — | — | — | |
| >9 mo | 43 (84.3) | 8(15.7) | 51 | <.0001 | 4.25 | 3.1-5.43 | |
| ≤9 mo | 5(7.1) | 65(92.9) | 70 | — | — | — | |
| . | Ab expression, n (%) . | . | |||||
|---|---|---|---|---|---|---|---|
| Variables . | Positive . | Negative . | Total . | P . | Odds ratio . | 95% CI . | |
| Analysis of entire cohort (n = 149) | |||||||
| Age at time of vaccination, y | ≤60 | 29 (50.0) | 29 (50.0) | 58 | .844 | 1 | 0.96-1.02 |
| >60 | 47 (51.6) | 44 (48.9) | 91 | — | — | — | |
| Sex | Female | 32 (52.5) | 29 (47.5) | 61 | .481 | 1.26 | 0.66-2.4 |
| Male | 41 (46.6) | 47 (53.4) | 88 | ||||
| Disease type | Indolent lymphoma | 38 (48.1) | 42 (52.5) | 80 | .87 | 1.04 | 0.55-2.00 |
| Aggressive lymphoma | 34 (49.3) | 35 (50.7) | 69 | — | — | — | |
| ALC (111 evaluated patients) | ≤0.9 × 103 /µL | 9 (20.5) | 35(79.5) | 44 | .002 | 3.32 | 1.53-7.21 |
| >0.9 × 103/µL | 42(54.5) | 35(45.5) | 77 | — | — | — | |
| Treatment status (detailed) | Treatment naïve | 25 (89.3) | 3 (10.7) | 28 | <.001 | 1 | |
| Active therapy* | 4(7.3) | 51 (92.7) | 55 | — | 0.039 | 0.01-0.12 | |
| After therapy | 44 (66.7) | 22 (33.3) | 66 | — | 4.17 | 1.13-15.32 | |
| Exposure to any anti-CD20 Abs | No | 25 (89.3) | 3 (10.7) | 28 | <.001 | 0.08 | 0.02-0.27 |
| Yes | 48(39.7) | 73(60.3) | 121 | — | — | — | |
| Analysis of patients treated with anti-CD20 abs (n = 121) | |||||||
| Age in time of vaccination, y | ≤60 | 20 (40.8) | 29 (59.2) | 49 | .832 | 1.08 | 0.52-2.27 |
| >60 | 28 (38.9) | 44 (61.1) | 72 | — | — | — | |
| Sex | Female | 18 (40.0) | 27 (60.0) | 45 | .954 | 0.98 | 0.46-2.08 |
| Male | 30 (39.5) | 46 (60.5) | 76 | — | — | — | |
| Disease type | Indolent lymphoma | 17 (30.9) | 38 (69.1) | 55 | .07 | 1.98 | 0.94-4.2 |
| Aggressive lymphoma | 31 (47.0) | 35 (53.0) | 66 | — | — | — | |
| ALC (107 evaluated patients) | ≤0.9 × 103/µL | 11(22.0) | 39 (78.0) | 50 | .006 | 3.19 | 1.37-7.45 |
| >0.9 × 103/µL | 27 (47.4) | 30(52.6) | 57 | — | — | — | |
| Time since last anti-CD20 abs (mo) | >6 mo | 44(66.7) | 22 (33.3) | 66 | <.001 | 25.5 | 8.16-77.6 |
| ≤6 mo | 4(7.3) | 51(92.7) | 55 | — | — | — | |
| >9 mo | 43 (84.3) | 8(15.7) | 51 | <.0001 | 4.25 | 3.1-5.43 | |
| ≤9 mo | 5(7.1) | 65(92.9) | 70 | — | — | — | |
Bold P values indicate statistically significant differences.
Active therapy refers to all patients treated with anti-CD20 Abs within 6 mo before vaccination, including patients receiving anti-CD20 Ab maintenance.